This is a phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate
the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and
have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and
no exclusion criteria will be randomized to receive either colchicine or placebo tablets for
30 days.
Phase:
Phase 3
Details
Lead Sponsor:
Montreal Heart Institute
Collaborators:
Bill and Melinda Gates Foundation DACIMA Software National Heart, Lung, and Blood Institute (NHLBI) The Government of Quebec